Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04569032
Title A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Seagen Inc.
Indications

peripheral T-cell lymphoma

angioimmunoblastic T-cell lymphoma

adult T-cell leukemia/lymphoma

follicular lymphoma

Therapies

Brentuximab vedotin + Cyclophosphamide + Doxorubicin + Prednisone

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP


No variant requirements are available.